Pazopanib Efficacy May Depend on Histologic Types of Soft Tissue Sarcoma

Share this content:
There appear to be differences in the efficacy of pazopanib treatment among histologic types of soft tissue sarcoma.
There appear to be differences in the efficacy of pazopanib treatment among histologic types of soft tissue sarcoma.

There appear to be differences in the efficacy of pazopanib treatment among histologic types of soft tissue sarcoma, a study published in the journal Cancer has shown.1

Pazopanib was approved by the U.S. Food and Drug Administration for the treatment of patients with advanced soft tissue sarcoma who have received prior chemotherapy. Approval was based on findings from the PALETTE study, which demonstrated a 3-month improvement in median progression-free survival with pazopanib compared with placebo.

Because the efficacy and safety of pazopanib in Japanese patients with soft tissue sarcoma had not been evaluated previously in a large-scale cohort, the researchers sought to assess the efficacy and safety of pazopanib in 156 Japanese patients with relapsed disease.

For the retrospective study, researchers analyzed the real-life, postmarketing surveillance data of 20 patients with local recurrence, 104 with metastasis, and 32 with both.

Results showed that median progression-free survival was 15.4 weeks. Median progression-free survival for patients with leiomyosarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma, and liposarcoma was 18.6 weeks, 16.4 weeks, 15.3 weeks, and 8 weeks, respectively.

Median survival for all patients was 11.2 months, and was 20.1 months, 10.6 months, 9.5 months, and 7.3 months for patients with leiomyosarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma, and liposarcoma, respectively.

RELATED: Molecular Genetic Testing Should Be Mandatory for Sarcoma Management

In terms of safety, researchers found that pneumothorax and thrombocytopenia had occurred frequently, in addition to the main common toxicities like hypertension and liver enzyme abnormalities.

Reference

  1. Nakamura T, Matsumine A, Kawai A, et al. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: a Japanese Musculoskeletal Oncology Group (JMOG) study [published online ahead of print March 11, 2016]. Cancer. doi: 10.1002/cncr.29961.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters